Valneva reels in €84m in fresh financing to shore up vaccine pipeline

The proceeds are set to support ongoing R&D, including the Lyme candidate VLA15 (LB6V, developed in partnership with Pfizer) and the shigellosis candidate S4V, as well as to maintain commercial operations and strengthen the company’s balance sheet.

VLA15 is the only Phase 3‑stage Lyme disease vaccine programme in its indication. It targets what analysts describe as a US‑1bn‑plus market in Lyme‑endemic regions of the US and Europe. The 6‑valent OspA‑based vaccine is the furthest‑advanced preventive candidate against Lyme disease and sits at the centre of Valneva’s strategic bet. In March, Valneva and Pfizer announced that LB6V missed its primary statistical endpoint in the Phase 3 VALOR trial. The companies still reported a clinically relevant efficacy signal (around 73–74% prevention of Lyme disease) and described the data as “positive”, but the failure to clear the predefined 95% confidence‑interval threshold has triggered investor unease and at least one shareholder‑litigation‑watch note. However, Pfizer still intends to submit LB6V for approval, banking on the observed efficacy and on Lyme’s unmet‑vaccine status.

The new financing slots into a broader story of financial tightening and strategic narrowing. Valneva ended 2025 with about €110m in cash, and the fresh €84m should cover the group through key 2026 milestones, including regulatory decisions on Lyme and further progress on S4V. The company has already refinanced up to US$500m in debt with US‑based healthcare investor Pharmakon Advisors, and this latest equity‑style financing nudges the company onto a somewhat more sustainable, though still narrow, runway.